Health Care [ 6/12 ] | Biotechnology [ 43/75 ]
NASDAQ | Common Stock
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.
The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers.
It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant.
The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML.
It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -121.60 Decreased by -30.30 K% | -0.10 Decreased by -121.50 K% |
| Aug 12, 25 | -251.24 Decreased by -61.18 K% | -0.22 Decreased by -111.91 K% |
| May 7, 25 | -0.26 Increased by +42.22% | -0.21 Decreased by -25.00% |
| Mar 18, 25 | -0.44 Decreased by -12.82% | -0.31 Decreased by -43.46% |
| Nov 5, 24 | -0.40 Increased by +18.37% | -0.40 |
| Aug 8, 24 | -0.41 Increased by +8.89% | -0.42 Increased by +2.38% |
| May 9, 24 | -0.45 Decreased by -4.65% | -0.38 Decreased by -18.42% |
| Mar 20, 24 | -0.39 Increased by +25.00% | -0.50 Increased by +22.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -812.68 M Decreased by -2.85 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -1.57 B Decreased by -5.55 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -32.49 M Decreased by -5.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 3.69 M Decreased by -69.85% | -30.71 M Decreased by -16.95% | Decreased by -833.21% Decreased by -287.91% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -27.56 M Increased by +16.97% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.84 M Increased by +7.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -30.80 M Decreased by -8.34% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 12.23 M Increased by +N/A% | -26.26 M Decreased by -9.83% | Decreased by -214.80% Decreased by N/A% |